Where does Oncobeta International GMBH rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Oncobeta International GMBH ranks #49,305 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Oncobeta International GMBH hold?

Oncobeta International GMBH holds 5 US utility patents granted between 2016 and 2022, spanning 6 technology areas.

What is Oncobeta International GMBH's Innovation Score?

Oncobeta International GMBH has an Innovation Score of 29.8 out of 100 (32nd percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Oncobeta International GMBH focus on?

Oncobeta International GMBH's top technology area is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy) with 5 patents, ranking #681 of 1,943 assignees active in that subclass. Grants appear in 6 CPC subclasses total.

Is Oncobeta International GMBH's patent grant rate increasing or decreasing?

Oncobeta International GMBH's recent grant velocity is -33% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Oncobeta International GMBH's patents?

Oncobeta International GMBH's patents average 19.4 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Oncobeta International GMBH patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Oncobeta International GMBH

USPTO PatentsView assignee record - 5 granted patents across 6 technology areas, recorded in grant years 2016–2022. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Oncobeta ranks #49,305 of 49,997 tracked US assignees by granted-patent volume, with 5 patents across 6 technology areas.

#49,305
of 49,997 US assignees by volume: 32nd percentile
by Innovation Score (29.8/100): 19.4
avg claims per patent: -33%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R49305 · Foreign Corporation #49,305 · 5 grants

GRANTS-MICRO · BOTTOM-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-DOWN · BOOK-FULL

GRANTS-MICRO 5 grants
BOTTOM-DECILE #49,305/49,997
PHOTO-FINISH Omni-id Cayman
CPC-NARROW A61N · 6 areas
INNOV-THIN 29.8/100
CLAIMS-RICH 19.4 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DOWN -33% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Omni-id Cayman Limited (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Oncobeta’s 29.8 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 6.2 pts (21%) Velocity 3.3 pts (11%) Breadth 8.7 pts (29%) Claim depth 11.6 pts (39%)

Qualcomm Incorporated · highest

85
Oncobeta International · this assignee

30
3D Lighting… · lowest

7

What this shows Oncobeta's Innovation Score is 29.8/100 (32nd percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Oncobeta?

Each dot is one of Oncobeta’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Oncobeta’s own 19.4 claims/patent is ABOVE the 14.0 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Oncobeta vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Oncobeta's grants concentrate

Oncobeta International GMBH is a focused PatentsView assignee: 6 CPC subclasses with 100% of grants classified under A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy). Peak complete grant year is 2016 (2 grants) versus a trough of 1 in 2019. By volume, Oncobeta sits between Omni USA, Inc. and Ookuma Electronic Co., Ltd..

Oncobeta's three-year grant acceleration

Oncobeta International GMBH shows 1 grants in 2022–2024 against only 2 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Omni USA

5
Omni-id Cayman

5
Omnivision Semico…

5
Omorpho

5
Oncotracker

5
Oniris

5
Onset Computer Co…

5
Ookuma

5
Oncobeta Internat… ◀

5

What this shows Oncobeta holds 5 patents at rank #49,275, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Oncobeta

By rank, the assignees closest to #49,275 in granted patent volume.

Leaders in A61N (Electrotherapy)

Other assignees with the most granted patents in Oncobeta's primary technology class.

Oncobeta's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

30 32nd percentile higher than 32% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2022

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table

Oncobeta International GMBH patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2016	2	40.0%
2019	1	20.0%
2021	1	20.0%
2022	1	20.0%

Which technologies does Oncobeta International GMBH patent most?

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 5

G21G - Conversion OF Chemical ELEMENTS; Radioactive Sources 1

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 1

B33Y - Additive Manufacturing, i.e. Manufacturing OF Three-dimensional [3-D] Objects BY Additive Deposition, Additive Agglomeration OR Additive Layering, e.g. BY 3-D Printing, Stereolithography OR Selective Laser Sintering 1

G21F - Protection Against X-radiation, Gamma Radiation, Corpuscular Radiation OR Particle BOMBARDMENT; Treating Radioactively Contaminated MATERIAL; Decontamination Arrangements Therefor 1

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 1

Top 6 of 6 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Oncobeta International GMBH's patent record in context - here's where to go next.

Oncobeta International GMBH's lead technology class is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy), 100% of its portfolio - see every assignee active in that class. Explore A61N
Ranked #49,305 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Oncobeta International GMBH against Omni USA, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 29.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.